Stereotaxis (STXS) Change in Accured Expenses (2010 - 2026)
Stereotaxis (STXS) posted quarterly Change in Accured Expenses of -$587000.0 for Q1 2026, down 11840.0% year-over-year from N/an in Q1 2025, and down 453.77% quarter-over-quarter from -$106000.0 in Q4 2025.
Stereotaxis (STXS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Change in Accured Expenses for 17 consecutive years, with -$587000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 11840.0% year-over-year to -$587000.0; the TTM figure through Mar 2026 stood at -$605000.0 (down 264.46% YoY), while the FY2025 annual figure was -$13000.0, down 161.9% from the prior year.
- Change in Accured Expenses slipped to -$587000.0 in Q1 2026 per STXS's latest filing, from -$106000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.2 million in Q2 2023 and bottomed at -$1.5 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged -$67500.0 across 5 years, with a median of -$9500.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 19000.0% — and 2026, when it tumbled 11840.0%.
- Stereotaxis' Change in Accured Expenses stood at -$148000.0 in 2022, then sank by 120.27% to -$326000.0 in 2023, then jumped by 102.76% to $9000.0 in 2024, then sank by 1277.78% to -$106000.0 in 2025, then sank by 453.77% to -$587000.0 in 2026.
- Business Quant data shows STXS's Change in Accured Expenses at -$587000.0 in Q1 2026, -$106000.0 in Q4 2025, and $238000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 55.00 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 50.56 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 119.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | - |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 50.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | - |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 29.00 Mn |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | -587,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -587,000.00 |
| Mar 31, 2026 | -587,000.00 |
| Dec 31, 2025 | -106,000.00 |
| Dec 31, 2025 | -106,000.00 |
| Sep 30, 2025 | 238,000.00 |
| Sep 30, 2025 | 238,000.00 |
| Jun 30, 2025 | -150,000.00 |
| Jun 30, 2025 | -150,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Jun 30, 2024 | -466,000.00 |
| Jun 30, 2024 | -466,000.00 |
| Mar 31, 2024 | 192,000.00 |
| Mar 31, 2024 | 192,000.00 |
| Dec 31, 2023 | -326,000.00 |
| Dec 31, 2023 | -326,000.00 |